2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pieter Sonneveld, MD, PhD, Head of the Department of Hematology, Erasmus University Medical Center, discusses the SKY92 prognostic indicator (MMPROFILER) for multiple myeloma.
Sonneveld and his team collected the DNA of tumors cells of more than 350 newly diagnosed patients with multiple myeloma. They then worked to identify which genes were overactive in the tumor cells of those patients and did a principal component analysis to find out what the most important genes that are relevant for the prognosis of those patients.
Ninety-two genes were identified that represent important pathways in multiple myeloma biology, says Sonneveld. Based on this data, a tool was created that can be used to predict the prognosis of individual myeloma patients or cohorts of patients in large clinical trials.